<DOC>
	<DOC>NCT01734928</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of Pomalidomide, Bortezomib and Dexamethasone is compared to the combination of Bortezomib and Dexamethasone</brief_summary>
	<brief_title>Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must be â‰¥ 18yrs at the time of signing informed consent. Must have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis. Must have had at least 1 but no greater than 3 prior antimyeloma regimens. Must have documented disease progression during or after their last antimyeloma therapy. All subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles. Refractory to prior Bortezomibcontaining therapy under the 1.3 mg/m2 dose twice weekly dosing schedule. Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization. Nonsecretory multiple myeloma. Subjects with severe renal impairment requiring dialysis. Previous therapy with pomalidomide.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
</DOC>